Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
Buch in deiner Nähe kaufen
Beschreibung
This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities.
The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.
Offers cutting-edge information on the development of antibody drug conjugates and recombinant immunotoxins Explores related basic biological and chemical technologies and promotes new developments toward clinical applications Primarily aimed at postgraduate students, researchers and clinicians
Autor*in
Ulf Grawunder
Themen in »Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins«
Antibody based cancer therapy Antibody drug conjugates (ADC) Immunotoxin development Pyrrolobenzodiazepines Calicheamicin Substance P–Saporin antibodies pharmacotherapy
Stimmen zu »Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins«
()
()